The stock of Abeona Therapeutics Inc (ABEO) has seen a -50.90% decrease in the past week, with a -49.93% drop in the past month, and a -21.77% decrease in the past quarter. The volatility ratio for the week is 7.23%, and the volatility levels for the past 30 days are at 6.33% for ABEO. The simple moving average for the last 20 days is -49.60% for ABEO’s stock, with a simple moving average of -24.65% for the last 200 days.
Is It Worth Investing in Abeona Therapeutics Inc (NASDAQ: ABEO) Right Now?
The 36-month beta value for ABEO is at 1.44. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ABEO is 25.91M, and currently, shorts hold a 7.70% of that float. The average trading volume for ABEO on April 23, 2024 was 367.42K shares.
ABEO) stock’s latest price update
Abeona Therapeutics Inc (NASDAQ: ABEO)’s stock price has dropped by -48.23 in relation to previous closing price of 7.36. Nevertheless, the company has seen a loss of -50.90% in its stock price over the last five trading days. Reuters reported 2024-04-22 that Abeona Therapeutics said on Monday the U.S. health regulator had declined to approve its treatment for a rare skin blistering condition.
Analysts’ Opinion of ABEO
Many brokerage firms have already submitted their reports for ABEO stocks, with Cantor Fitzgerald repeating the rating for ABEO by listing it as a “Overweight.” The predicted price for ABEO in the upcoming period, according to Cantor Fitzgerald is $4 based on the research report published on November 11, 2020 of the previous year 2020.
B. Riley FBR, on the other hand, stated in their research note that they expect to see ABEO reach a price target of $5. The rating they have provided for ABEO stocks is “Buy” according to the report published on September 18th, 2020.
SVB Leerink gave a rating of “Outperform” to ABEO, setting the target price at $6 in the report published on February 10th of the previous year.
ABEO Trading at -48.91% from the 50-Day Moving Average
After a stumble in the market that brought ABEO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.71% of loss for the given period.
Volatility was left at 6.33%, however, over the last 30 days, the volatility rate increased by 7.23%, as shares sank -48.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.87% lower at present.
During the last 5 trading sessions, ABEO fell by -51.16%, which changed the moving average for the period of 200-days by -7.33% in comparison to the 20-day moving average, which settled at $7.38. In addition, Abeona Therapeutics Inc saw -23.95% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABEO starting from Seshadri Vishwas, who purchase 20,000 shares at the price of $4.39 back on Feb 06 ’24. After this action, Seshadri Vishwas now owns 528,260 shares of Abeona Therapeutics Inc, valued at $87,800 using the latest closing price.
Alvino Mark, the Director of Abeona Therapeutics Inc, sale 7,084 shares at $5.11 during a trade that took place back on Jan 17 ’24, which means that Alvino Mark is holding 62,816 shares at $36,199 based on the most recent closing price.
Stock Fundamentals for ABEO
Current profitability levels for the company are sitting at:
- -13.77 for the present operating margin
- 0.09 for the gross margin
The net margin for Abeona Therapeutics Inc stands at -15.48. The total capital return value is set at -0.95. Equity return is now at value -260.60, with -84.53 for asset returns.
Based on Abeona Therapeutics Inc (ABEO), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -6.85. The debt to equity ratio resting at 0.36. The interest coverage ratio of the stock is -115.31.
Currently, EBITDA for the company is -45.0 million with net debt to EBITDA at 0.21. When we switch over and look at the enterprise to sales, we see a ratio of 27.09. The receivables turnover for the company is 1.43for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.15.
Conclusion
In conclusion, Abeona Therapeutics Inc (ABEO) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
